Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What fueled the previous growth in the immuno-oncology drugs market?

The market dimension for immuno-oncology medications has seen a significant increase in the past few years. The market is projected to expand from $94.16 billion in 2024 to $106.92 billion in 2025, with a compound annual growth rate (CAGR) of 13.6%. The historical growth can be traced back to an upturn in cancer incidence, robust economic progress in developing markets, escalated spending in healthcare, and amplified pharmaceutical R&D expenditure.

What will be the immuno-oncology drugs market size in the future?

The size of the home healthcare market is forecasted to expand swiftly in the coming years, projected to reach $646.13 billion in 2029, with a compound annual growth rate (CAGR) of 11.2%. Factors like global health occurrences, telehealth proliferation, home-based patient care models, focus-driven care, and individualized medicine contribute to growth in the prediction period. Future trends of the forecast period involve technological advancements, the growth of remote monitoring, the collaboration of IoT and wearable tech, attention to chronic disease management, a broader home health tech ecosystem, as well as cooperation and alliances within the healthcare ecosystem.

Get your immuno-oncology drugs market report here!

https://www.thebusinessresearchcompany.com/report/immuno-oncology-drug-global-market-report

What main drivers are fueling expansion in the immuno-oncology drugs market?

The global increase in cancer incidences is expected to spur the growth of the immuno-oncology drugs market. For example, data from the American Cancer Society in January 2022 indicates an estimated 1.9 million new cancer cases and 609,360 cancer-related deaths in the US, which translates into roughly 1,670 fatalities daily. Lung, prostate, bowel, and female breast cancer are the four most prevalent cancer types worldwide, representing 43% of all new cancer diagnoses. The same types of cancer account for 43% of new cases globally. Consequently, the escalating cancer incidence rates around the world are projected to stimulate the demand for immuno-oncology drugs in the coming years.

What key areas define the segmentation of the global immuno-oncology drugs market?

The immuno-oncology drugs market covered in this report is segmented –

1) By Type: Immune Checkpoint Inhibitors, Immune System Modulators, Other Monoclonal Antibodies, Cancer Vaccines, Others

2) By Therapeutic Application: Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer, Other Therapeutic Application

3) By End-Users: Hospitals, Clinics, Ambulatory Surgical Centers, Others

Subsegments:

1) By Immune Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors

2) By Immune System Modulators: Cytokines, Interferons, Colony-Stimulating Factors

3) By Other Monoclonal Antibodies: Targeted Monoclonal Antibodies, Bispecific Antibodies

4) By Cancer Vaccines: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines

5) By Others: Adoptive Cell Transfer Therapies, Oncolytic Virus Therapies

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3455&type=smp

Who are the dominant players expanding their reach in the immuno-oncology drugs market?

Major companies operating in the immuno-oncology drugs market include F. Hoffmann-La Roche Ltd., Merck & Co., Bristol-Myers Squibb Company, Amgen Inc, Johnson & Johnson, AstraZeneca Plc, Eli Lilly and Company, Novartis International AG, Pfizer Inc., Sanofi S.A., Arlak Biotech, Apikos Pharma, Kolaz biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals, Astellas Pharma Inc, Otsuka Pharmaceutical Co, Ltd, Legend Biotech Co, Zai Lab, Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, Baxter International Inc., GlaxoSmithKline plc, Affimed Therapeutics, Autolus Therapeutics, Cellectis, Celyad, GammaDelta Therapeutics, Immunocore, European Medical Center (EMC), Yauza Medical Center, Celon Pharma, Veropharm, Biocad, Selvita, OncoArendi Therapeutics Mabion, Fate Therapeutics, Forty-Seven, Arcus Biosciences, Gritstone Oncology, Rakuten Medical, Rubius Therapeutics, Allogene Therapeutics, Celgene Corporation, Bayer AG, Incyte Corporation, Recepta Biopharma, CSC Pharmaceuticals International, Blanver EN, Sandoz Brazil, Life Pharma, Julphar, NewBridge Pharmaceuticals, Eurolab

How are evolving market trends shaping immuno-oncology drugs Strategies?

Leading firms in the immuno-oncology drugs market are joining forces to create and bring to market a new checkpoint antibody, aiming to improve the effectiveness of cancer therapies. These strategic partnerships encourage innovation by facilitating the exchange of knowledge across various disciplines, thus leading to a quicker development of combination therapies, personalized treatments, and innovative drug delivery systems. For example, in March 2023, BioNTech SE, a German company, teamed up with OncoC4 Inc., a pharmaceutical company from the United States, to jointly create and market a checkpoint antibody, specifically the anti-CTLA-4 monoclonal antibody candidate termed as ONC-392. The objective of this collaboration is to augment cancer treatment alternatives for various solid tumor conditions.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3455

Which regions are emerging as leaders in the immuno-oncology drugs market?

North America was the largest region in the immuno-oncology drugs market in 2024. The regions covered in the immuno-oncology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Therapeutic Proteins Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/therapeutic-proteins-global-market-report

Antibody Drug Conjugates Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-global-market-report

Drugs for Immunotherapy Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/drugs-for-immunotherapy-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: